Free Trial
→ How one AI fund pays investors every Thursday (From Investors Alley) (Ad)tc pixel Free KPTI Stock Alerts

Karyopharm Therapeutics (KPTI) Financials

Karyopharm Therapeutics logo
$0.39 -0.04 (-9.45%)
As of 11:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Karyopharm Therapeutics

Annual Income Statements for Karyopharm Therapeutics

This table shows Karyopharm Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Consolidated Net Income / (Loss)		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Net Income / (Loss) Continuing Operations		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Total Pre-Tax Income 		-76 -118 -109 -178 -200 -196 -124 -165 -143 -76 -196
Total Operating Income		 -76 -119 -111 -180 -189 -172 -98 -142 -130 -119 -91
Total Gross Profit		 0.23 0.25 0.15 30 41 105 206 152 141 139 140
Total Revenue		 0.23 0.25 0.15 30 41 108 210 157 146 145 146
Operating Revenue		 0.23 0.25 0.15 30 41 108 210 157 146 145 146
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 2.71 3.40 5.21 4.94 6.01 5.95
Operating Cost of Revenue		 - - - - - 2.71 3.40 5.21 4.94 6.01 5.95
Total Operating Expenses		 76 119 111 210 230 277 305 294 271 259 231
Selling, General & Admin Expense		 16 22 24 49 108 126 144 145 132 115 105
Research & Development Expense		 60 98 87 161 122 151 161 149 139 143 126
Total Other Income / (Expense), net		 0.07 0.90 1.29 1.50 -10 -24 -26 -23 -13 43 -105
Interest Expense		 0.00 - 0.00 2.49 16 27 26 25 24 -7.28 108
Interest & Investment Income		 0.10 0.90 1.28 4.03 5.42 2.82 0.58 2.36 11 7.40 2.77
Other Income / (Expense), net		 -0.03 -0.00 0.01 -0.03 -0.05 0.21 -0.09 -0.08 -0.36 28 0.15
Income Tax Expense		 0.00 0.00 0.14 0.03 0.04 0.31 0.27 0.37 0.32 0.06 0.04
Basic Earnings per Share		 ($2.43) ($3.32) ($2.92) ($3.14) ($3.22) ($2.72) ($1.65) ($2.02) ($18.79) ($9.41) ($17.93)
Weighted Average Basic Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 81.87M 7.62M 8.13M 10.94M
Diluted Earnings per Share		 ($2.43) ($3.32) ($2.92) ($3.14) ($3.22) ($2.72) ($1.65) ($2.02) ($18.79) ($14.00) ($17.93)
Weighted Average Diluted Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 81.87M 7.62M 8.46K 10.94M
Weighted Average Basic & Diluted Shares Outstanding		 31.14M 35.62M 37.52M 56.78M 61.96M 72.04M 75.22M 113.34M 115.07M 126.24M 18.34M

Quarterly Income Statements for Karyopharm Therapeutics

This table shows Karyopharm Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Consolidated Net Income / (Loss)		 -42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Net Income / (Loss) Continuing Operations		 -42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Total Pre-Tax Income 		-42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Total Operating Income		 -38 -34 -28 -26 -31 -33 -24 -15 -18 -27 -23
Total Gross Profit		 32 31 41 37 29 29 37 42 33 34 32
Total Revenue		 34 33 43 39 31 30 38 44 34 35 33
Operating Revenue		 34 33 43 39 31 30 38 44 34 35 33
Total Cost of Revenue		 1.49 1.91 1.47 1.30 1.33 1.30 1.05 2.11 1.48 1.35 1.09
Operating Cost of Revenue		 1.49 1.91 1.47 1.30 1.33 1.30 1.05 2.11 1.48 1.35 1.09
Total Operating Expenses		 70 65 69 64 60 62 61 57 50 60 55
Selling, General & Admin Expense		 31 30 31 28 27 27 28 27 23 27 26
Research & Development Expense		 39 35 38 36 33 35 33 31 28 34 29
Total Other Income / (Expense), net		 -3.90 -3.53 52 -5.76 0.39 9.83 -13 -18 -84 4.37 -44
Interest Expense		 6.21 5.88 -36 11 11 11 11 11 75 13 13
Interest & Investment Income		 2.52 2.16 1.93 1.83 1.48 1.00 0.61 0.55 0.61 0.51 0.72
Other Income / (Expense), net		 -0.21 0.20 14 3.79 10 20 -2.21 -7.42 -10 16 -32
Income Tax Expense		 0.13 0.07 0.07 0.03 -0.11 0.04 0.04 0.03 -0.07 0.00 0.00
Basic Earnings per Share		 ($5.49) ($4.85) $2.26 ($3.85) ($0.20) ($2.77) ($4.32) ($3.82) ($9.35) ($1.02) ($2.32)
Weighted Average Basic Shares Outstanding		 7.62M 7.70M 8.07K 8.34M 121.86M 8.47M 8.62M 8.67M 10.94M 22.01M 28.94M
Diluted Earnings per Share		 ($5.49) ($4.85) ($2.97) ($3.85) ($0.15) ($2.77) ($4.32) ($3.82) ($9.35) ($1.24) ($2.32)
Weighted Average Diluted Shares Outstanding		 7.62M 7.70M 10.30K 8.34M 126.81K 8.47M 8.62M 8.67M 10.94M 24.72K 28.94M
Weighted Average Basic & Diluted Shares Outstanding		 115.07M 117.71M 124.68M 125.31M 126.24M 8.64M 8.67M 17.05B 18.34M 22.66M 22.68M

Annual Cash Flow Statements for Karyopharm Therapeutics

This table details how cash moves in and out of Karyopharm Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.37 -92 -8.70 49 12 -42 108 -61 -84 9.62 -1.94
Net Cash From Operating Activities		 -51 -94 -84 -159 -191 -160 -107 -150 -93 -127 -75
Net Cash From Continuing Operating Activities		 -51 -94 -84 -159 -191 -160 -107 -150 -93 -127 -75
Net Income / (Loss) Continuing Operations		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Consolidated Net Income / (Loss)		 -76 -118 -110 -178 -200 -196 -124 -165 -143 -76 -196
Depreciation Expense		 0.32 0.63 0.72 0.74 0.97 0.97 0.79 0.62 0.53 0.34 0.30
Amortization Expense		 0.00 1.78 1.20 1.45 5.81 9.49 2.34 -0.01 -3.28 3.87 10
Non-Cash Adjustments To Reconcile Net Income		 14 18 22 17 16 25 38 37 24 -57 83
Changes in Operating Assets and Liabilities, net		 9.72 4.00 0.99 -0.17 -14 0.10 -25 -22 29 1.31 27
Net Cash From Investing Activities		 -67 -91 25 -108 78 -54 142 -104 7.94 95 43
Net Cash From Continuing Investing Activities		 -67 -91 25 -108 78 -54 142 -104 7.94 95 43
Purchase of Property, Plant & Equipment		 -2.83 -1.42 -0.07 -2.36 -0.21 -0.15 -0.21 -0.12 0.00 -0.14 0.00
Purchase of Investments		 -64 -305 -135 -243 -178 -275 -45 -226 -159 -59 0.00
Sale and/or Maturity of Investments		 0.00 216 159 138 257 221 193 122 167 154 43
Net Cash From Financing Activities		 113 93 51 316 124 172 74 194 1.12 42 30
Net Cash From Continuing Financing Activities		 113 93 51 316 124 172 74 194 1.12 42 30
Repayment of Debt		 - - - - - - - 0.00 0.00 0.00 -0.25
Repurchase of Common Equity		 - - - - - - - - 0.00 -2.59 -6.46
Issuance of Debt		 - - 0.00 167 - - - 0.00 0.00 83 27
Issuance of Common Equity		 113 93 51 149 51 172 14 194 1.12 1.45 9.51
Other Financing Activities, net		 0.00 0.00 0.04 0.00 74 0.00 60 0.00 0.00 -41 0.00
Cash Interest Paid		 - - - 0.00 0.00 11 16 34 21 39 11

Quarterly Cash Flow Statements for Karyopharm Therapeutics

This table details how cash moves in and out of Karyopharm Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 8.61 -22 54 -12 -10 -24 -0.05 -1.05 23 30 -36
Net Cash From Operating Activities		 -19 -44 -38 -19 -26 -39 -19 -5.86 -12 -23 -25
Net Cash From Continuing Operating Activities		 -19 -44 -38 -19 -26 -39 -19 -5.86 -12 -23 -25
Net Income / (Loss) Continuing Operations		 -42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Consolidated Net Income / (Loss)		 -42 -37 24 -32 -31 -23 -37 -33 -102 -22 -67
Depreciation Expense		 0.08 0.09 0.09 0.08 0.08 0.08 0.08 0.12 0.02 0.01 -0.00
Amortization Expense		 -0.80 -0.70 0.73 1.88 1.97 2.34 2.60 2.76 2.44 2.36 2.47
Non-Cash Adjustments To Reconcile Net Income		 5.70 5.51 -53 0.77 -9.78 -16 6.22 11 83 -6.42 39
Changes in Operating Assets and Liabilities, net		 18 -11 -10 9.89 13 -1.93 9.65 14 5.37 3.71 1.12
Net Cash From Investing Activities		 27 22 51 7.47 15 15 18 4.81 5.00 3.20 -10
Net Cash From Continuing Investing Activities		 27 22 51 7.47 15 15 18 4.81 5.00 3.20 -10
Net Cash From Financing Activities		 0.26 0.00 41 - 0.68 0.00 0.36 - 30 50 -0.90
Net Cash From Continuing Financing Activities		 0.26 0.00 41 - 0.68 0.00 0.36 - 30 50 -0.90
Repurchase of Common Equity		 - - - - - 0.00 - - - -0.43 -1.47
Issuance of Common Equity		 0.26 - - - 0.68 0.00 - - 9.16 50 0.57
Effect of Exchange Rate Changes		 - -0.02 -0.01 0.04 -0.02 0.01 0.01 0.00 - 0.00 -0.00

Annual Balance Sheets for Karyopharm Therapeutics

This table presents Karyopharm Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 220 215 180 180 295 313 305 358 240 164 108
Total Current Assets		 208 178 132 148 279 277 276 350 234 156 103
Cash & Equivalents		 151 58 50 69 129 86 190 135 52 62 61
Short-Term Investments		 55 117 80 77 133 163 38 143 139 46 3.20
Accounts Receivable		 - - - - 7.86 13 22 47 27 31 26
Inventories, net		 - - - - 0.35 2.64 4.11 4.22 3.04 4.74 4.04
Prepaid Expenses		 2.03 1.97 2.08 1.75 7.29 9.29 14 20 12 12 9.19
Plant, Property, & Equipment, net		 2.75 3.48 2.84 2.19 3.05 2.22 1.64 1.14 0.61 0.40 0.10
Total Noncurrent Assets		 9.83 34 46 30 13 34 28 6.87 5.91 7.56 5.17
Other Noncurrent Operating Assets		 0.77 - - - 11 9.36 27 6.24 5.61 7.22 4.82
Other Noncurrent Nonoperating Assets		 0.40 0.48 0.48 0.29 0.71 0.72 0.64 0.63 0.30 0.34 0.35
Total Liabilities & Shareholders' Equity		 220 215 180 180 295 313 305 358 240 164 108
Total Liabilities		 14 17 18 51 245 263 385 375 377 350 401
Total Current Liabilities		 12 15 16 49 46 60 74 66 69 92 92
Short-Term Debt		 - - - - - - - - - 0.00 21
Accounts Payable		 6.29 3.81 4.75 5.67 0.99 4.45 1.60 2.77 3.12 5.11 4.00
Accrued Expenses		 5.83 11 11 21 41 53 69 58 61 61 64
Other Current Liabilities		 0.06 0.10 0.08 0.13 2.15 2.53 2.99 4.72 4.96 27 2.55
Total Noncurrent Liabilities		 1.24 1.95 1.67 1.36 199 202 311 309 307 258 309
Long-Term Debt		 - - - 0.00 110 118 169 170 171 95 95
Other Noncurrent Operating Liabilities		 - - - - 87 84 142 139 136 164 214
Total Equity & Noncontrolling Interests		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Total Preferred & Common Equity		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 207 198 162 129 50 51 -80 -17 -136 -186 -293
Common Stock		 345 455 529 625 923 1,120 1,099 1,328 1,351 1,378 1,467
Retained Earnings		 -138 -257 -366 -495 -873 -1,070 -1,179 -1,344 -1,487 -1,563 -1,759
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.28 -0.27 -0.22 -0.04 0.52 0.19 -0.64 -0.16 -0.36 0.07

Quarterly Balance Sheets for Karyopharm Therapeutics

This table presents Karyopharm Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 270 204 214 189 128 105 96 131 111
Total Current Assets		 263 198 209 185 120 98 90 126 106
Cash & Equivalents		 44 31 85 73 39 39 38 91 55
Short-Term Investments		 165 118 67 61 31 13 8.21 0.00 10
Accounts Receivable		 38 31 38 32 35 33 32 23 30
Inventories, net		 3.11 2.77 3.48 4.67 4.77 4.99 3.97 3.60 3.99
Prepaid Expenses		 13 15 15 15 10 8.25 8.03 8.53 7.41
Plant, Property, & Equipment, net		 0.69 0.72 0.63 0.50 0.32 0.24 0.12 0.09 0.09
Total Noncurrent Assets		 6.05 5.37 4.81 4.23 7.15 6.77 6.36 4.99 4.85
Other Noncurrent Operating Assets		 5.67 5.07 4.51 3.92 6.81 6.42 6.01 4.68 4.53
Other Noncurrent Nonoperating Assets		 0.38 0.30 0.30 0.31 0.34 0.35 0.35 0.32 0.32
Total Liabilities & Shareholders' Equity		 270 204 214 189 128 105 96 131 111
Total Liabilities		 370 373 346 349 334 344 365 397 441
Total Current Liabilities		 62 65 58 61 90 99 87 117 134
Short-Term Debt		 - - - - - 6.25 13 32 40
Accounts Payable		 0.94 5.03 2.80 5.78 5.87 2.60 5.39 4.28 7.66
Accrued Expenses		 56 55 50 50 57 63 66 76 79
Other Current Liabilities		 5.42 5.46 5.01 5.61 27 27 2.94 4.49 7.46
Total Noncurrent Liabilities		 308 308 288 288 243 245 278 280 307
Long-Term Debt		 171 171 118 94 95 90 108 106 111
Other Noncurrent Operating Liabilities		 138 137 171 194 148 155 170 174 196
Total Equity & Noncontrolling Interests		 -100 -169 -132 -160 -206 -239 -269 -266 -330
Total Preferred & Common Equity		 -100 -169 -132 -160 -206 -239 -269 -266 -330
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -100 -169 -132 -160 -206 -239 -269 -266 -330
Common Stock		 1,346 1,356 1,369 1,373 1,381 1,385 1,388 1,516 1,519
Retained Earnings		 -1,445 -1,524 -1,501 -1,533 -1,587 -1,624 -1,657 -1,782 -1,849
Accumulated Other Comprehensive Income / (Loss)		 -0.74 -0.52 -0.61 -0.22 -0.32 -0.25 -0.26 0.04 0.04

Annual Metrics And Ratios for Karyopharm Therapeutics

This table displays calculated financial ratios and metrics derived from Karyopharm Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 9.17% -38.40% 942.21% 0.00% 34.80% 164.31% 94.12% -25.14% -7.03% -0.55% 0.57%
EBITDA Growth		 -54.43% 6.74% -18.30% -38.08% -2.71% 11.70% 40.92% -48.78% 6.37% 34.53% 7.73%
EBIT Growth		 -56.94% 7.02% -17.97% -37.74% -5.23% 9.34% 42.70% -44.66% 8.71% 29.91% 0.54%
NOPAT Growth		 -57.00% 7.01% -17.79% 3.59% -5.22% 9.21% 42.82% -44.70% 8.90% 7.79% 24.06%
Net Income Growth		 -55.96% 7.28% -17.71% 0.00% -11.87% 1.66% 36.78% -33.20% 13.43% 46.60% -156.52%
EPS Growth		 -36.63% 12.05% 3.77% 0.00% -2.55% 15.53% 39.34% -22.42% 13.43% 25.60% -28.07%
Operating Cash Flow Growth		 -82.77% 10.25% 12.65% 0.00% -19.93% 16.03% 33.15% -39.62% 38.00% -37.49% 40.88%
Free Cash Flow Firm Growth		 -72.75% 4.76% 11.30% -78.28% 84.77% -349.40% 73.80% -284.95% 50.38% 31.02% -7.40%
Invested Capital Growth		 -45.57% -13.71% -254.64% 100.00% 0.00% -1.90% -34.94% 13.54% -24.94% -27.12% -9.79%
Revenue Q/Q Growth		 3.73% 16.67% 1,260.17% 0.00% 0.00% 0.00% 76.84% -37.11% 0.11% -2.16% 2.48%
EBITDA Q/Q Growth		 -2.50% 1.87% -10.65% 0.00% -3,068.61% -1,820.38% 45.83% -133.43% -3.69% 18.43% -8.55%
EBIT Q/Q Growth		 -2.87% 1.90% -10.40% 0.00% 0.00% 0.00% 45.82% -129.79% -3.29% 15.62% -8.02%
NOPAT Q/Q Growth		 -2.90% 1.89% -10.26% 0.00% 0.00% 0.00% 46.09% -131.71% -3.14% 5.18% 12.90%
Net Income Q/Q Growth		 -2.71% 1.89% -10.36% 0.00% 0.00% 0.00% 39.83% -87.69% -2.38% 12.64% -57.31%
EPS Q/Q Growth		 0.00% 5.50% -6.44% 0.00% 0.00% 0.00% 40.00% -87.04% -2.38% 18.42% -24.69%
Operating Cash Flow Q/Q Growth		 -8.80% 0.44% 16.40% 0.00% 4.35% 5.24% 34.38% -53.81% 8.18% -6.01% 15.65%
Free Cash Flow Firm Q/Q Growth		 0.00% 3.42% 12.03% -851.61% -142.99% -5,432.87% 53.13% -34.62% 14.77% -47.37% 43.38%
Invested Capital Q/Q Growth		 -21.63% -32.74% -157.42% 100.00% -3.65% -3.38% 12.13% -4.77% -13.50% -0.53% -12.96%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 97.50% 98.38% 96.68% 96.62% 95.86% 95.93%
EBITDA Margin		 -46,666.40% -70,653.25% -8,019.88% -585.88% -446.38% -149.13% -45.39% -90.20% -90.84% -59.79% -54.85%
Operating Margin		 -47,630.40% -71,903.90% -8,133.21% -592.97% -462.85% -159.00% -46.84% -90.53% -88.71% -82.24% -62.10%
EBIT Margin		 -47,631.20% -71,897.40% -8,138.26% -593.08% -462.98% -158.80% -46.88% -90.58% -88.95% -62.69% -62.00%
Profit (Net Income) Margin		 -47,272.40% -71,153.90% -8,036.39% -588.10% -488.08% -181.59% -59.14% -105.23% -97.99% -52.62% -134.21%
Tax Burden Percent		 100.00% 100.13% 100.05% 100.01% 100.02% 100.16% 100.22% 100.22% 100.23% 100.07% 100.02%
Interest Burden Percent		 99.25% 98.84% 98.70% 99.15% 105.40% 114.17% 125.89% 115.91% 109.92% 83.88% 216.44%
Effective Tax Rate		 0.00% 0.00% -0.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -58.34% -60.77% -88.43% -275.61% -801.99% -391.29% 852.05% 343.18% 187.23% 47.43% 81.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -54.65% -55.94% -72.43% -199.58% -128.37% -56.46% -31.81% -42.89% -43.40% -44.98% -66.38%
Return on Assets (ROA)		 -54.24% -55.37% -71.52% -197.91% -135.33% -64.56% -40.13% -49.83% -47.81% -37.75% -143.71%
Return on Common Equity (ROCE)		 -58.34% -60.77% -88.43% -275.61% -801.99% -391.29% 852.05% 343.18% 187.23% 47.43% 81.86%
Return on Equity Simple (ROE_SIMPLE)		 -59.58% -67.54% -99.63% 0.00% -400.99% -388.31% 155.75% 992.38% 0.00% 41.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 -83 -78 -131 -126 -132 -120 -69 -100 -91 -84 -63
NOPAT Margin		 -33,341.28% -50,332.73% -8,137.18% -415.08% -324.00% -111.30% -32.79% -63.37% -62.09% -57.57% -43.47%
Net Nonoperating Expense Percent (NNEP)		 -16.40% -16.64% 0.92% -59.53% -86.05% -48.29% -49.15% -74.77% -80.01% 40.01% 454.07%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -64.87% -261.22% 91.46% 40.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 2.50% 1.62% 3.32% 3.38% 4.14% 4.07%
SG&A Expenses to Revenue		 8,632.80% 15,550.65% 1,549.53% 161.02% 263.68% 116.96% 68.56% 92.57% 90.31% 79.48% 72.03%
R&D to Revenue		 39,097.60% 56,453.25% 6,683.68% 531.95% 299.17% 139.53% 76.66% 94.64% 95.01% 98.62% 86.00%
Operating Expenses to Revenue		 47,730.40% 72,003.90% 8,233.21% 692.97% 562.85% 256.49% 145.21% 187.21% 185.32% 178.10% 158.03%
Earnings before Interest and Taxes (EBIT)		 -119 -111 -131 -180 -189 -172 -98 -142 -130 -91 -91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -117 -109 -129 -178 -183 -161 -95 -142 -133 -87 -80
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.39 2.39 3.40 0.00 24.18 22.54 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.39 2.39 3.40 0.00 24.18 22.54 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1,893.81 2,517.46 274.54 18.75 29.44 10.54 2.32 1.76 0.68 0.58 859.16
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% -29.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 1,055.76 1,381.18 164.84 18.75 25.64 9.08 2.00 1.06 0.53 0.49 859.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 2.21 2.33 -2.12 -10.21 -1.25 -0.51 -0.47
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 2.21 2.33 -2.12 -10.21 -1.25 -0.51 -0.40
Financial Leverage		 -1.05 -1.07 -1.21 -1.36 -3.13 -3.14 7.73 1.83 0.86 0.11 -0.12
Leverage Ratio		 1.08 1.10 1.24 1.39 5.93 6.06 -21.23 -6.89 -3.92 -1.26 -0.57
Compound Leverage Factor		 1.07 1.08 1.22 1.38 6.25 6.92 -26.73 -7.98 -4.30 -1.05 -1.23
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 68.82% 70.00% 188.90% 110.85% 492.38% -103.49% -87.77%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.47%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 68.82% 70.00% 188.90% 110.85% 492.38% -103.49% -74.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 0.00% 31.18% 30.00% -88.90% -10.85% -392.38% 203.49% 187.77%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.60 -0.73 -1.78 -1.20 -1.29 -1.09 -1.71
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.85 0.98 0.69 0.77 0.16 0.16 -0.91
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.60 -0.73 -1.78 -1.20 -1.29 -1.09 -1.45
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.83 -0.98 -2.46 -1.71 -1.88 -1.13 -2.16
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 1.17 1.31 0.95 1.09 0.23 0.17 -1.15
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.83 -0.98 -2.46 -1.71 -1.88 -1.13 -1.83
Altman Z-Score		 14.05 8.72 -0.37 0.00 -2.23 -2.81 -4.23 -4.73 -8.86 -13.64 163.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.74 7.99 3.00 0.00 6.01 4.59 3.74 5.31 3.37 1.70 1.12
Quick Ratio		 11.61 7.86 2.96 0.00 5.82 4.35 3.41 4.93 3.14 1.51 0.98
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -80 -76 -97 -173 -26 -118 -31 -119 -59 -41 -44
Operating Cash Flow to CapEx		 -6,640.47% -120,558.57% -118,898.39% -6,733.69% -92,632.04% -110,506.21% -50,526.42% -126,740.68% 0.00% -89,778.87% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -69.32 -1.68 -4.36 -1.19 -4.77 -2.49 0.00 -0.41
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -63.83 -12.20 -5.90 -4.11 -5.98 -3.89 0.00 -0.70
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -64.77 -12.21 -5.91 -4.12 -5.99 -3.89 0.00 -0.70
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.34 0.28 0.36 0.68 0.47 0.49 0.72 1.07
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 10.42 11.86 4.51 3.94 5.03 5.13
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 1.81 1.01 1.25 1.36 1.54 1.36
Fixed Asset Turnover		 0.08 0.05 0.64 0.00 0.00 41.06 108.69 112.96 167.37 288.74 579.63
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 1.00 1.12 2.38 1.68 1.46 1.31
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 35.02 30.77 80.85 92.54 72.54 71.15
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 201.73 362.10 291.62 268.36 236.43 269.26
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 366.69 324.71 153.20 217.73 250.04 279.47
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 -129.93 68.16 219.27 143.17 58.93 60.93
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -13 -47 0.00 -106 -108 -146 -126 -158 -200 -220
Invested Capital Turnover		 -0.03 -0.01 -0.05 -1.29 -0.77 -1.01 -1.65 -1.15 -1.03 -0.81 -0.69
Increase / (Decrease) in Invested Capital		 -3.64 -1.59 -34 47 -106 -2.01 -38 20 -31 -43 -20
Enterprise Value (EV)		 264 213 265 569 1,048 981 420 167 78 71 125,568
Market Capitalization		 473 388 441 569 1,204 1,139 486 276 99 85 125,494
Book Value per Share		 $5.55 $3.93 $2.82 $0.00 $0.79 $0.69 ($1.05) ($0.21) ($1.19) ($1.48) ($0.02)
Tangible Book Value per Share		 $5.55 $3.93 $2.82 $0.00 $0.79 $0.69 ($1.05) ($0.21) ($1.19) ($1.48) ($0.02)
Total Capital		 198 162 129 0.00 160 168 90 153 35 -91 -156
Total Debt		 0.00 0.00 0.00 0.00 110 118 169 170 171 95 137
Total Long-Term Debt		 0.00 0.00 0.00 0.00 110 118 169 170 171 95 116
Net Debt		 -210 -175 -176 0.00 -155 -158 -66 -109 -21 -14 73
Capital Expenditures (CapEx)		 1.42 0.07 0.06 2.36 0.21 0.15 0.21 0.12 0.00 0.14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -13 -14 -48 0.00 -31 -35 -33 5.22 -28 -45 -32
Debt-free Net Working Capital (DFNWC)		 162 115 99 0.00 232 216 202 284 164 64 32
Net Working Capital (NWC)		 162 115 99 0.00 232 216 202 284 164 64 11
Net Nonoperating Expense (NNE)		 35 32 -1.62 52 67 76 55 66 52 -7.19 133
Net Nonoperating Obligations (NNO)		 -210 -175 -176 0.00 -156 -159 -66 -110 -21 -14 73
Total Depreciation and Amortization (D&A)		 2.41 1.92 1.90 2.18 6.79 10 3.13 0.61 -2.75 4.21 10
Debt-free, Cash-free Net Working Capital to Revenue		 -5,266.00% -9,345.45% -2,972.77% 0.00% -75.45% -32.75% -15.76% 3.33% -18.94% -30.65% -21.67%
Debt-free Net Working Capital to Revenue		 64,987.20% 74,779.22% 6,165.48% 0.00% 567.87% 200.15% 96.22% 180.97% 112.61% 44.22% 21.97%
Net Working Capital to Revenue		 64,987.20% 74,779.22% 6,165.48% 0.00% 567.87% 200.15% 96.22% 180.97% 112.61% 44.22% 7.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) ($2.02) ($18.75) ($0.63) ($17.93)
Adjusted Weighted Average Basic Shares Outstanding		 35.88M 41.90M 45.90M 60.86M 0.00 74.63M 79.16M 81.87M 7.61M 121.86M 10.94M
Adjusted Diluted Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) ($2.02) ($18.75) ($0.93) ($17.93)
Adjusted Weighted Average Diluted Shares Outstanding		 35.88M 41.90M 45.90M 60.86M 0.00 74.63M 79.16M 81.87M 7.61M 126.81K 10.94M
Adjusted Basic & Diluted Earnings per Share		 ($3.32) ($2.92) ($2.81) ($3.14) $0.00 ($2.72) ($1.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 35.62M 37.52M 45.90M 56.80M 0.00 72.04M 75.22M 113.34M 7.67M 126.24M 18.34M
Normalized Net Operating Profit after Tax (NOPAT)		 -83 -78 -91 -126 -132 -120 -69 -100 -91 -84 -63
Normalized NOPAT Margin		 -33,341.28% -50,332.73% -5,693.25% -415.08% -324.00% -111.30% -32.79% -63.37% -62.09% -57.57% -43.47%
Pre Tax Income Margin		 -47,272.40% -71,063.64% -8,032.46% -588.02% -487.98% -181.31% -59.01% -105.00% -97.77% -52.58% -134.18%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -72.17 -12.10 -6.32 -3.78 -5.69 -5.45 0.00 -0.84
NOPAT to Interest Expense		 0.00 0.00 0.00 -50.51 -8.47 -4.43 -2.64 -3.98 -3.81 0.00 -0.59
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -73.12 -12.11 -6.33 -3.78 -5.70 -5.45 0.00 -0.84
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -51.46 -8.48 -4.44 -2.65 -3.99 -3.81 0.00 -0.59
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.30%

Quarterly Metrics And Ratios for Karyopharm Therapeutics

This table displays calculated financial ratios and metrics derived from Karyopharm Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 114,533,991.00 115,067,083.00 117,710,263.00 124,683,681.00 - 126,240,054.00 8,639,904.00 8,671,278.00 - 18,343,968.00 22,662,943.00
DEI Adjusted Shares Outstanding		 7,635,599.00 7,671,139.00 7,847,351.00 8,312,245.00 - 8,416,004.00 8,639,904.00 8,671,278.00 - 18,343,968.00 22,662,943.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.48 -4.87 3.03 -3.86 - -2.79 -4.31 -3.82 - -1.22 -2.96
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.50% -14.40% 13.86% 7.70% -9.50% -9.39% -11.35% 13.57% 11.58% 16.83% -11.86%
EBITDA Growth		 -13.88% -7.49% 57.05% 35.48% 50.65% 67.77% -83.91% 3.79% -33.01% 27.63% -117.97%
EBIT Growth		 -12.21% -7.70% 53.21% 27.85% 44.33% 59.98% -92.40% -0.65% -31.75% 22.95% -105.29%
NOPAT Growth		 -11.63% -9.26% -35.46% 15.92% 17.26% 1.49% 39.12% 42.09% 42.96% 19.53% 7.63%
Net Income Growth		 -8.65% -9.48% 172.91% 7.05% 26.43% 37.20% -256.57% -3.29% -232.03% 4.56% -79.92%
EPS Growth		 -8.65% -9.48% 172.91% 7.05% 58.33% 42.89% -45.45% 0.78% -146.70% 55.23% 46.30%
Operating Cash Flow Growth		 30.76% -131.23% -49.81% 34.12% -38.88% 10.84% 51.43% 69.88% 54.17% 41.70% -33.34%
Free Cash Flow Firm Growth		 111.53% -142.26% 114.21% 1,330.11% 316.66% 179.73% 5,235.18% -136.16% -65.78% 80.39% 193.74%
Invested Capital Growth		 -24.94% -7.63% -20.40% -43.52% -27.12% -22.97% -17.05% 2.29% -9.79% -20.84% -25.18%
Revenue Q/Q Growth		 -6.28% -1.84% 29.16% -9.36% -21.25% -1.73% 26.37% 16.12% -22.63% 2.90% -4.66%
EBITDA Q/Q Growth		 -21.76% 11.78% 61.95% -57.87% 6.87% 42.38% -117.11% 17.41% -28.75% 68.65% -553.92%
EBIT Q/Q Growth		 -21.97% 11.72% 58.81% -62.70% 5.89% 36.54% -98.01% 14.89% -23.19% 62.89% -427.60%
NOPAT Q/Q Growth		 -20.95% 10.71% -18.66% 34.39% -19.02% -6.31% 26.67% 37.59% -17.24% -49.97% 15.82%
Net Income Q/Q Growth		 -21.25% 10.70% 163.68% -234.80% 4.03% 23.78% -58.78% 11.07% -208.50% 78.09% -199.32%
EPS Q/Q Growth		 -21.25% 10.70% 163.68% -234.80% 42.31% 26.91% -55.96% 11.57% -144.76% 86.74% -87.10%
Operating Cash Flow Q/Q Growth		 37.06% -135.27% 11.95% 49.47% -32.68% -51.04% 52.04% 68.66% -101.84% -92.15% -9.69%
Free Cash Flow Firm Q/Q Growth		 246.50% -363.34% 101.61% 19,654.32% -50.38% -49.61% 8.01% -233.89% 146.96% 165.63% 75.87%
Invested Capital Q/Q Growth		 -13.50% 6.67% -13.29% -19.60% -0.53% 9.73% -7.84% 0.16% -12.96% 0.65% -11.72%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 95.60% 94.23% 96.58% 96.65% 95.64% 95.67% 97.23% 95.20% 95.65% 96.16% 96.75%
EBITDA Margin		 -114.81% -103.18% -30.40% -52.94% -62.61% -36.71% -63.06% -44.85% -74.63% -22.74% -155.95%
Operating Margin		 -112.03% -101.91% -65.72% -67.77% -102.42% -110.80% -64.30% -34.56% -52.36% -76.31% -67.38%
EBIT Margin		 -112.66% -101.32% -32.31% -57.99% -69.30% -44.75% -70.12% -51.40% -81.83% -29.51% -163.32%
Profit (Net Income) Margin		 -123.97% -112.79% 55.61% -82.70% -100.78% -78.17% -98.22% -75.21% -299.89% -63.86% -200.48%
Tax Burden Percent		 100.31% 100.19% 99.72% 100.09% 99.65% 100.15% 100.11% 100.10% 99.93% 100.00% 100.00%
Interest Burden Percent		 109.70% 111.11% -172.59% 142.47% 145.93% 174.40% 139.91% 146.18% 366.70% 216.36% 122.75%
Effective Tax Rate		 0.00% 0.00% 0.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 187.23% 136.68% 88.42% 67.28% 47.43% 33.36% 66.60% 58.11% 81.86% 82.70% 78.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -54.97% -53.68% -18.39% -37.47% -49.72% -38.30% -60.38% -51.28% -87.62% -34.42% -221.52%
Return on Assets (ROA)		 -60.49% -59.75% 31.65% -53.44% -72.31% -66.89% -84.56% -75.04% -321.10% -74.48% -271.92%
Return on Common Equity (ROCE)		 187.23% 136.68% 88.42% 67.28% 47.43% 33.36% 66.60% 58.11% 81.86% 82.70% 78.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 86.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -24 -28 -18 -22 -23 -17 -11 -12 -19 -16
NOPAT Margin		 -78.42% -71.34% -65.54% -47.44% -71.69% -77.56% -45.01% -24.19% -36.65% -53.42% -47.17%
Net Nonoperating Expense Percent (NNEP)		 -23.46% -39.36% 101.83% -34.93% -49.45% 0.78% 439.44% 129.68% 307.32% 10.18% 79.07%
Return On Investment Capital (ROIC_SIMPLE)		 -76.24% -1,088.00% 196.59% 28.07% 23.95% 21.03% 11.93% 7.17% 8.01% 14.69% 8.82%
Cost of Revenue to Revenue		 4.40% 5.77% 3.42% 3.35% 4.36% 4.33% 2.77% 4.80% 4.35% 3.84% 3.25%
SG&A Expenses to Revenue		 90.94% 89.20% 72.62% 71.25% 89.02% 91.13% 75.08% 60.41% 66.82% 76.10% 77.52%
R&D to Revenue		 116.69% 106.94% 89.68% 93.17% 109.04% 115.34% 86.45% 69.35% 81.18% 96.38% 86.61%
Operating Expenses to Revenue		 207.63% 196.14% 162.30% 164.42% 198.06% 206.46% 161.53% 129.76% 148.01% 172.48% 164.13%
Earnings before Interest and Taxes (EBIT)		 -38 -34 -14 -22 -21 -13 -27 -23 -28 -10 -55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -39 -34 -13 -21 -19 -11 -24 -20 -25 -7.97 -52
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.68 1.24 0.70 0.70 0.58 0.22 0.27 0.40 859.16 0.68 1.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.53 1.39 0.47 0.43 0.49 0.40 0.59 0.92 859.66 0.99 2.10
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.25 -1.01 -0.89 -0.59 -0.51 -0.46 -0.40 -0.45 -0.47 -0.52 -0.46
Long-Term Debt to Equity		 -1.25 -1.01 -0.89 -0.59 -0.51 -0.46 -0.37 -0.40 -0.40 -0.40 -0.34
Financial Leverage		 0.86 0.33 0.50 0.30 0.11 -0.12 -0.02 -0.08 -0.12 -0.15 -0.23
Leverage Ratio		 -3.92 -2.48 -2.52 -1.77 -1.26 -0.89 -0.86 -0.67 -0.57 -0.55 -0.38
Compound Leverage Factor		 -4.30 -2.75 4.34 -2.52 -1.83 -1.55 -1.20 -0.97 -2.09 -1.19 -0.47
Debt to Total Capital		 492.38% 7,878.78% -826.39% -143.59% -103.49% -86.01% -66.95% -81.18% -87.77% -108.33% -84.58%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.37% -8.41% -13.47% -25.28% -22.53%
Long-Term Debt to Total Capital		 492.38% 7,878.78% -826.39% -143.59% -103.49% -86.01% -62.59% -72.76% -74.30% -83.06% -62.04%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -392.38% -7,778.78% 926.39% 243.59% 203.49% 186.01% 166.95% 181.18% 187.77% 208.33% 184.58%
Debt to EBITDA		 -1.29 -1.27 -1.00 -0.88 -1.09 -1.50 -1.28 -1.63 -1.71 -1.79 -1.44
Net Debt to EBITDA		 0.16 -0.16 0.29 0.37 0.16 -0.40 -0.59 -1.01 -0.91 -0.61 -0.82
Long-Term Debt to EBITDA		 -1.29 -1.27 -1.00 -0.88 -1.09 -1.50 -1.20 -1.47 -1.45 -1.37 -1.05
Debt to NOPAT		 -1.88 -1.85 -1.29 -1.07 -1.13 -1.14 -1.19 -1.65 -2.16 -2.34 -2.62
Net Debt to NOPAT		 0.23 -0.24 0.37 0.45 0.17 -0.30 -0.55 -1.03 -1.15 -0.80 -1.50
Long-Term Debt to NOPAT		 -1.88 -1.85 -1.29 -1.07 -1.13 -1.14 -1.11 -1.48 -1.83 -1.80 -1.93
Altman Z-Score		 -7.59 -9.23 -8.33 -9.97 -12.24 -16.29 -21.16 -23.28 165.51 -17.86 -23.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.37 3.04 3.62 3.00 1.70 1.33 0.99 1.03 1.12 1.08 0.79
Quick Ratio		 3.14 2.75 3.30 2.69 1.51 1.16 0.85 0.89 0.98 0.97 0.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5.01 -13 0.21 42 21 11 11 -15 7.14 19 33
Operating Cash Flow to CapEx		 0.00% -22,423.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.81 -2.24 0.00 3.70 1.86 0.96 1.01 -1.38 0.10 1.51 2.54
Operating Cash Flow to Interest Expense		 -2.99 -7.43 0.00 -1.71 -2.30 -3.55 -1.67 -0.53 -0.16 -1.81 -1.90
Operating Cash Flow Less CapEx to Interest Expense		 -2.99 -7.46 0.00 -1.71 -2.30 -3.55 -1.67 -0.53 -0.16 -1.81 -1.90
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.49 0.53 0.57 0.65 0.72 0.86 0.86 1.00 1.07 1.17 1.36
Accounts Receivable Turnover		 3.94 4.24 4.15 4.26 5.03 4.29 3.87 4.48 5.13 5.16 4.67
Inventory Turnover		 1.36 1.67 1.62 1.58 1.54 1.43 1.18 1.34 1.36 1.43 1.34
Fixed Asset Turnover		 167.37 179.16 208.99 251.38 288.74 273.06 314.84 462.01 579.63 731.81 867.58
Accounts Payable Turnover		 1.68 0.78 2.27 1.83 1.46 0.99 1.85 1.04 1.31 1.18 1.18
Days Sales Outstanding (DSO)		 92.54 86.12 88.04 85.69 72.54 85.17 94.30 81.51 71.15 70.77 78.17
Days Inventory Outstanding (DIO)		 268.36 218.79 225.97 230.33 236.43 254.90 310.14 271.99 269.26 254.82 272.10
Days Payable Outstanding (DPO)		 217.73 466.80 160.72 199.20 250.04 368.58 197.55 351.87 279.47 309.12 310.59
Cash Conversion Cycle (CCC)		 143.17 -161.89 153.29 116.82 58.93 -28.52 206.88 1.62 60.93 16.47 39.68
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -158 -147 -167 -199 -200 -181 -195 -195 -220 -219 -244
Invested Capital Turnover		 -1.03 -0.99 -0.95 -0.88 -0.81 -0.87 -0.76 -0.72 -0.69 -0.76 -0.67
Increase / (Decrease) in Invested Capital		 -31 -10 -28 -60 -43 -34 -28 4.56 -20 -38 -49
Enterprise Value (EV)		 78 196 68 64 71 57 81 131 125,568 149 308
Market Capitalization		 99 174 102 103 85 31 37 57 125,494 102 221
Book Value per Share		 ($1.19) ($1.47) ($1.12) ($1.28) ($1.48) ($1.63) ($27.65) ($31.05) ($0.02) ($14.48) ($14.57)
Tangible Book Value per Share		 ($1.19) ($1.47) ($1.12) ($1.28) ($1.48) ($1.63) ($27.65) ($31.05) ($0.02) ($14.48) ($14.57)
Total Capital		 35 2.17 -14 -66 -91 -111 -143 -149 -156 -128 -179
Total Debt		 171 171 118 94 95 95 96 121 137 138 151
Total Long-Term Debt		 171 171 118 94 95 95 90 108 116 106 111
Net Debt		 -21 22 -34 -39 -14 25 44 75 73 47 86
Capital Expenditures (CapEx)		 0.00 0.20 0.00 0.00 -0.05 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -16 -1.24 -10 -45 -40 -47 -31 -32 -50 -53
Debt-free Net Working Capital (DFNWC)		 164 133 151 123 64 30 4.90 15 32 41 12
Net Working Capital (NWC)		 164 133 151 123 64 30 -1.35 2.59 11 9.03 -28
Net Nonoperating Expense (NNE)		 15 14 -52 14 8.88 0.18 20 22 90 3.66 51
Net Nonoperating Obligations (NNO)		 -21 22 -35 -40 -14 25 44 74 73 47 86
Total Depreciation and Amortization (D&A)		 -0.73 -0.62 0.82 1.96 2.05 2.42 2.68 2.88 2.46 2.38 2.46
Debt-free, Cash-free Net Working Capital to Revenue		 -18.94% -11.40% -0.85% -6.94% -30.65% -28.20% -34.09% -21.60% -21.67% -32.81% -35.91%
Debt-free Net Working Capital to Revenue		 112.61% 94.71% 103.61% 83.04% 44.22% 21.02% 3.57% 10.59% 21.97% 27.31% 8.49%
Net Working Capital to Revenue		 112.61% 94.71% 103.61% 83.04% 44.22% 21.02% -0.98% 1.82% 7.59% 5.98% -19.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($82.35) ($4.80) $2.25 ($3.90) ($0.20) ($2.77) ($4.32) ($3.82) ($9.35) ($1.02) ($2.32)
Adjusted Weighted Average Basic Shares Outstanding		 507.73K 7.70M 8.07M 8.33M 121.86M 8.47M 8.62M 8.67M 10.94M 22.01M 28.94M
Adjusted Diluted Earnings per Share		 ($82.35) ($4.80) ($3.00) ($3.90) ($0.15) ($2.77) ($4.32) ($3.82) ($9.35) ($1.24) ($2.32)
Adjusted Weighted Average Diluted Shares Outstanding		 507.73K 7.70M 10.30M 8.33M 126.81K 8.47M 8.62M 8.67M 10.94M 24.72K 28.94M
Adjusted Basic & Diluted Earnings per Share		 ($82.35) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($9.35) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.67M 7.85M 8.31M 8.35M 126.24M 8.64M 8.67M 17.05B 18.34M 22.66M 22.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -24 -28 -18 -22 -23 -17 -11 -12 -19 -16
Normalized NOPAT Margin		 -78.42% -71.34% -65.54% -47.44% -71.69% -77.56% -45.01% -24.19% -36.65% -53.42% -47.17%
Pre Tax Income Margin		 -123.59% -112.57% 55.76% -82.62% -101.14% -78.05% -98.11% -75.14% -300.08% -63.85% -200.48%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -6.12 -5.70 0.00 -1.98 -1.89 -1.22 -2.37 -2.06 -0.37 -0.82 -4.15
NOPAT to Interest Expense		 -4.26 -4.02 0.00 -1.62 -1.95 -2.12 -1.52 -0.97 -0.17 -1.49 -1.20
EBIT Less CapEx to Interest Expense		 -6.12 -5.74 0.00 -1.98 -1.88 -1.22 -2.37 -2.06 -0.37 -0.82 -4.15
NOPAT Less CapEx to Interest Expense		 -4.26 -4.05 0.00 -1.62 -1.95 -2.12 -1.52 -0.97 -0.17 -1.49 -1.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.30% -3.54% -3.72%

Financials Breakdown Chart

Key Financial Trends

Karyopharm Therapeutics’ second-quarter 2026 results show modest cost control, but the company remains unprofitable and cash-flow negative. Revenue was $33.4 million, down from $35.1 million in the first quarter and $37.9 million in the second quarter of 2025. Gross profit remained strong at $32.3 million, representing a gross margin of approximately 97%, but this was not enough to cover operating expenses.

Operating expenses declined to $54.9 million in Q2 2026 from $60.5 million in Q1 and $61.3 million in Q2 2025. Both selling, general and administrative expense and research and development expense fell sequentially. However, the company still reported a $22.5 million operating loss and a $67.0 million net loss, with interest expense and other expenses significantly worsening the bottom line.

Liquidity is a major concern. Cash and equivalents declined to $55.0 million at June 30, 2026, from $90.9 million at March 31. Including short-term investments, immediately available resources totaled approximately $65.1 million. The company used $35.9 million of cash during the quarter, including $24.9 million of operating cash burn.

  • High gross margins: Q2 2026 gross profit was $32.3 million on $33.4 million of revenue, producing an approximately 97% gross margin.
  • Operating expense reduction: Total operating expenses fell to $54.9 million from $60.5 million in Q1 2026, with research and development expense declining by roughly $4.8 million sequentially.
  • Revenue remains meaningful: Quarterly revenue has generally remained in the $30 million-to-$44 million range across the reported periods, providing an established commercial base.
  • Q1 equity financing improved liquidity: Karyopharm raised approximately $50.2 million through common-stock issuance in Q1 2026, temporarily increasing its cash balance.
  • Operating loss improved from late 2025: The Q2 2026 operating loss of $22.5 million was narrower than the $26.8 million loss in Q1 2026 and the $47.2 million loss in Q4 2025.
  • Noncash adjustments remain material: Q2 operating cash flow benefited from $38.5 million of noncash adjustments, including amortization. This means reported cash burn does not directly track the size of the net loss in every quarter.
  • Quarterly data includes restatements and calculated figures: Some 2024 and 2025 results were identified as restated or calculated, so investors should rely on the latest company filings when comparing historical trends.
  • Revenue is declining year over year: Q2 2026 revenue fell approximately 12% from $37.9 million in Q2 2025 and approximately 22% from $42.8 million in Q2 2024.
  • Persistent net losses: Karyopharm reported net losses in each of the provided recent quarters except Q2 2024, when it recorded a $23.8 million profit. The Q2 2026 net loss was $67.0 million, or $2.32 per basic share.
  • Weak balance sheet and ongoing cash burn: Total liabilities of $441.5 million exceeded total assets of $111.3 million, resulting in negative shareholders’ equity of $330.2 million. With approximately $65.1 million of cash and short-term investments and $24.9 million of quarterly operating cash burn, additional financing may be needed if this pace continues.
  • Debt and interest costs are substantial: Short- and long-term debt totaled approximately $151.3 million at June 30, 2026. Interest expense was $13.1 million in Q2, further pressuring earnings and cash resources.
  • Potential dilution risk: The company has relied on equity financing, including the $50.2 million common-stock issuance in Q1 2026. Future capital raises could dilute existing shareholders.
10/14/26 11:00 AM ETAI Generated. May Contain Errors.

Karyopharm Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Karyopharm Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Karyopharm Therapeutics' net income appears to be on a downward trend, with a most recent value of -$196.04 million in 2025, falling from -$75.78 million in 2014. The previous period was -$76.42 million in 2024. Find out what analysts predict for Karyopharm Therapeutics in the coming months.

Karyopharm Therapeutics' total operating income in 2025 was -$90.71 million, based on the following breakdown:
  • Total Gross Profit: $140.12 million
  • Total Operating Expenses: $230.83 million

Over the last 11 years, Karyopharm Therapeutics' total revenue changed from $229 thousand in 2014 to $146.07 million in 2025, a change of 63,684.7%.

In the past 11 quarters, Karyopharm Therapeutics' cash and equivalents has ranged from $30.63 million in Q1 2024 to $90.85 million in Q1 2026, and is currently $54.98 million as of their latest financial filing in Q2 2026.

Karyopharm Therapeutics had total debt of $136.92 million at the end of 2025, a 44.7% increase from 2024, and none in 2015.

Over the last 10 years, Karyopharm Therapeutics' book value per share changed from 5.55 in 2015 to -0.02 in 2025.


Related Companies

Financial statements for NASDAQ:KPTI last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
AI Microcap Teams With Gentex on Next-Gen Military Helmets
Morgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...
Capital Trends | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...
Weiss Ratings | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel